title: Improved decision making for prioritizing tumor targeting antibodies in human xenografts: Utility of fluorescence imaging to verify tumor target expression, antibody binding and optimization of dosage and application schedule.
abstract: Preclinical efficacy studies of antibodies targeting a tumor-associated antigen are only justified when the expression of the relevant antigen has been demonstrated. Conventionally, antigen expression level is examined by immunohistochemistry of formalin-fixed paraffin-embedded tumor tissue section. This method represents the diagnostic "gold standard" for tumor target evaluation, but is affected by a number of factors, such as epitope masking and insufficient antigen retrieval. As a consequence, variances and discrepancies in histological staining results can occur, which may influence decision-making and therapeutic outcome. To overcome these problems, we have used different fluorescence-labeled therapeutic antibodies targeting human epidermal growth factor receptor (HER) family members and insulin-like growth factor-1 receptor (IGF1R) in combination with fluorescence imaging modalities to determine tumor antigen expression, drug-target interaction, and biodistribution and tumor saturation kinetics in non-small cell lung cancer xenografts. For this, whole-body fluorescence intensities of labeled antibodies, applied as a single compound or antibody mixture, were measured in Calu-1 and Calu-3 tumor-bearing mice, then ex vivo multispectral tumor tissue analysis at microscopic resolution was performed. With the aid of this simple and fast imaging method, we were able to analyze the tumor cell receptor status of HER1-3 and IGF1R, monitor the antibody-target interaction and evaluate the receptor binding sites of anti-HER2-targeting antibodies. Based on this, the most suitable tumor model, best therapeutic antibody, and optimal treatment dosage and application schedule was selected. Predictions drawn from obtained imaging data were in excellent concordance with outcome of conducted preclinical efficacy studies. Our results clearly demonstrate the great potential of combined in vivo and ex vivo fluorescence imaging for the preclinical development and characterization of monoclonal antibodies.
authors.affiliation: a Discovery Oncology, Pharmaceutical Research and Early Development, Roche Innovation Center Munich , Penzberg , Germany.
authors.forename: Michael
authors.initials: M
authors.lastname: Dobosz
authors.affiliation: a Discovery Oncology, Pharmaceutical Research and Early Development, Roche Innovation Center Munich , Penzberg , Germany.
authors.forename: Ute
authors.initials: U
authors.lastname: Haupt
authors.affiliation: a Discovery Oncology, Pharmaceutical Research and Early Development, Roche Innovation Center Munich , Penzberg , Germany.
authors.forename: Werner
authors.initials: W
authors.lastname: Scheuer
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology*; D000951:Antigens, Neoplasm / Q000032:analysis*; D002289:Carcinoma, Non-Small-Cell Lung; D066246:ErbB Receptors / Q000032:analysis; D006801:Humans; D008175:Lung Neoplasms; D051379:Mice; D061848:Optical Imaging / Q000379:methods*; D017526:Receptor, IGF Type 1 / Q000032:analysis; D023041:Xenograft Model Antitumor Assays
chemical_list: D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D066246:ErbB Receptors; D017526:Receptor, IGF Type 1
keywords: Antibody development; In vivo histology; antigen expression; cancer; immunohistochemistry; multispectral fluorescence imaging; optical Imaging; tumor-target evaluation